Evolving Strategies for Management of Early-Stage and Metastatic Triple-Negative Breast Cancer
Release Date: June 02, 2014
Expiration Date: June 01, 2015
This activity is supported by an educational grant from Eisai, Inc.
Jointly provided by Dannemiller and Targeted Healthcare Communications.
Oncologists, surgical oncologists, radiation oncologists, and oncology nurses.
Upon completion of this activity, the participant should be able to:
- Review clinical trial data on current and emerging neoadjuvant treatments for patients with early-stage TNBC.
- Evaluate efficacy and safety data for currently available chemotherapeutic agents for patients with metastatic TNBC.
- Develop and implement individualized treatment plans with consideration for key patient and clinical factors for patients with TNBC.
Statement of Need
This activity is designed to educate oncologists and oncology nurses on evolving strategies for management of early-stage and metastatic triple-negative breast cancer. The discussion includes information regarding incidence, prognosis, and molecular subtypes of TNBC. It includes data on neoadjuvant treatment for early-stage TNBC, including benefits, such as improved pCR rates; and information on anthracycline-, taxane-, platinum-, and microtubule-inhibitor-based regimens. The CME also includes information on: recurrence and survival data and locations of metastases, treatment responses with chemotherapy, single-agent versus combination therapy, preferred NCCN single agents, and study 301 subgroup data. It details the factors to consider when selecting treatments, including: personalizing goals of chemotherapy in metastatic TNBC; tolerance of side effects; and quality-of-life considerations.
Method of Participation
This activity should take approximately 2 hours to complete. Participants should first read the objectives and other introductory CME/CE information and then proceed to the educational activity. To receive credit for this activity, participants must complete the post-test with a passing score of 80% and then complete the evaluation. Credit is provided through June 01, 2015. No credit will be given after this date. There is no fee to participate in this activity.
In the event you have questions about this activity or are unable to retrieve the certificate, please email email@example.com and a certificate will be emailed within 2 weeks.
- Computer, tablet, or smart phone with internet access
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Targeted Healthcare Communications and Dannemiller. Dannemiller is accredited by the ACCME to provide continuing medical education for physicians.
Dannemiller designates this enduring material for a maximum of 2.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAPA accepts certificates of participation for educational activities certified for Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 2.00 AMA PRA Category 1 Credit(s)™ for completing this program.
William J. Gradisher, MD, FASCO, FACP
Betsy Bramsen Professor of Breast Oncology & Professor of Medicine
Director, Maggie Daley Center for Women's Cancer Care
Robert H. Lurie Comprehensive Cancer Center
Northwestern University Feinberg School of Medicine
Denise A. Yardley, MD
Sarah Cannon Research Institute
Tennessee Oncology, PLLC
Mateusz Opyrchal, MD, PhD
Assistant Professor of Oncology
Co-Director, RPCI Breast Disease Site Research Group
Department of Medicine
Roswell Park Cancer Institute
In accordance with the Accreditation Council for Continuing Medical Education (ACCME), Dannemiller requires that any person who is in a position to control the content of a CME activity must disclose all relevant financial relationships they have with a commercial interest.
The following faculty stated they have no relevant financial disclosure:
- William J. Gradishar, MD, FASCO, FACP (Faculty)
- Denise A. Yardley, MD (Faculty)
- Mateusz Opyrchal, MD, PhD (Faculty Reviewer, Clinical Content Reviewer)
Sandra Kear, MS, managing editor of Targeted Healthcare Communications; Katherine DeYoung, PhD, Hitt Medical Writing, LLC; and Ashley Amerson, CE Project Manager, Dannemiller, Inc., have no financial relationships with commercial interests.
To resolve identified/potential conflicts of interest, the educational content was fully reviewed by a Clinical Content Reviewer who has nothing to disclose. The resulting certified activity was found to provide educational content that is current, evidence based and commercially balanced.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Dannemiller, Targeted Healthcare Communications, or Eisai, Inc. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon the information contained within this educational activity.